These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 8830346)

  • 1. Oxidative stress and antioxidant therapy in Parkinson's disease.
    Ebadi M; Srinivasan SK; Baxi MD
    Prog Neurobiol; 1996 Jan; 48(1):1-19. PubMed ID: 8830346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective strategies in Parkinson's disease : an update on progress.
    Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
    CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
    Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC
    Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
    Gerlach M; Desser H; Youdim MB; Riederer P
    J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress and the pathogenesis of Parkinson's disease.
    Jenner P; Olanow CW
    Neurology; 1996 Dec; 47(6 Suppl 3):S161-70. PubMed ID: 8959985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
    PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
    Olanow CW
    Mov Disord; 1993; 8 Suppl 1():S1-7. PubMed ID: 8302302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals.
    Chiueh CC; Andoh T; Lai AR; Lai E; Krishna G
    Neurotox Res; 2000; 2(2-3):293-310. PubMed ID: 16787846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia.
    Chiueh CC; Wu RM; Mohanakumar KP; Sternberger LM; Krishna G; Obata T; Murphy DL
    Ann N Y Acad Sci; 1994 Nov; 738():25-36. PubMed ID: 7832434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
    Zuo L; Motherwell MS
    Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
    Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
    Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease.
    Youdim MB; Riederer P
    Mov Disord; 1993; 8 Suppl 1():S8-13. PubMed ID: 8302308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
    Jellinger KA
    J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative stress: a role in the pathogenesis of Parkinson's disease.
    Götz ME; Freyberger A; Riederer P
    J Neural Transm Suppl; 1990; 29():241-9. PubMed ID: 2193108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
    Cacabelos R
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons.
    Sharma SK; Ebadi M
    Antioxid Redox Signal; 2003 Jun; 5(3):251-64. PubMed ID: 12880480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
    Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
    Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin protects against behavioral deficits, dopamine loss and oxidative stress in homocysteine model of Parkinson's disease.
    Paul R; Phukan BC; Justin Thenmozhi A; Manivasagam T; Bhattacharya P; Borah A
    Life Sci; 2018 Jan; 192():238-245. PubMed ID: 29138117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.